Efficacy of Dulotide Combined with Dagliprazin in the Treatment of Type 2 Diabetes Mellitus Complicated with Coronary Heart Disease
Objective To analyze the value of dapagliflozin+dulotide therapy in patients with type 2 diabetes melli-tus and coronary heart disease.Methods A total of 72 patients with type 2 diabetes mellitus complicated with coro-nary heart disease admitted to Panzhou People's Hospital from February 2023 to February 2024 were selected as the research objects.According to the dice method,they were divided into single drug group and combined group,with 36 cases in each group.The single drug group was treated with dulaglutide,and the combined group added dapagliflozin for treatment.The levels of inflammatory indexes,blood glucose indexes,incidence of cardiovascular events and qual-ity of life scores were compared between the two groups.Results There were no significant differences in the levels of inflammation index and blood glucose index between the two groups before treatment(both P>0.05).After treatment,the above indexes of the combined group were better than those of the single drug group,and the differences were sta-tistically significant(both P<0.05).The total incidence of cardiovascular events in the combined group was 2.78%,which was lower than 19.44%in the single drug group,and the difference was statistically significant(χ2=5.063,P=0.024).There was no significant difference in quality of life score between the two groups before treatment(P>0.05).After treatment,the quality of life score of the combined group was higher than that of the single drug group,and the difference was statistically significant(P<0.05).Conclusion Dulotide+dapagliflozin can enhance the prevention and control effect of cardiovascular and cerebrovascular events,enable patients to accurately control blood glucose,im-prove inflammation,and improve the quality of life of patients with type 2 diabetes and coronary heart disease.
DapagliflozinCoronary heart diseaseQuality of lifeDulotideIndicators of inflammationType 2 diabetes
万方数据
维普
